CA3042039C - Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability - Google Patents

Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability Download PDF

Info

Publication number
CA3042039C
CA3042039C CA3042039A CA3042039A CA3042039C CA 3042039 C CA3042039 C CA 3042039C CA 3042039 A CA3042039 A CA 3042039A CA 3042039 A CA3042039 A CA 3042039A CA 3042039 C CA3042039 C CA 3042039C
Authority
CA
Canada
Prior art keywords
vancomycin
compound
ala
date
vana
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3042039A
Other languages
English (en)
French (fr)
Other versions
CA3042039A1 (en
Inventor
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA3042039A1 publication Critical patent/CA3042039A1/en
Application granted granted Critical
Publication of CA3042039C publication Critical patent/CA3042039C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3042039A 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability Active CA3042039C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415191P 2016-10-31 2016-10-31
US62/415,191 2016-10-31
PCT/US2017/059289 WO2018081797A1 (en) 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability

Publications (2)

Publication Number Publication Date
CA3042039A1 CA3042039A1 (en) 2018-05-03
CA3042039C true CA3042039C (en) 2023-09-26

Family

ID=62024092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3042039A Active CA3042039C (en) 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability

Country Status (6)

Country Link
US (1) US10934326B2 (https=)
EP (1) EP3532483A4 (https=)
JP (1) JP7104424B2 (https=)
AU (1) AU2017348434B2 (https=)
CA (1) CA3042039C (https=)
WO (1) WO2018081797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270685B (en) 2017-05-22 2022-09-01 Insmed Inc Cleavable derivatives of lipoglycopeptide and their uses
EP4139328A4 (en) * 2020-04-20 2024-05-22 The Scripps Research Institute GUANIDINE-MODIFIED C-TERMINAL VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS
CN117069794B (zh) * 2023-06-20 2024-02-13 广州中医药大学(广州中医药研究院) 一种糖肽类抗生素荧光探针化合物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919756A (en) * 1996-06-28 1999-07-06 Eli Lilly And Company Amides
CA2497159A1 (en) 2002-08-30 2004-03-11 K.U. Leuven Research And Development Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents
US8778874B2 (en) 2004-11-29 2014-07-15 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
WO2012129493A1 (en) * 2011-03-24 2012-09-27 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives
US10081655B2 (en) * 2011-11-14 2018-09-25 Jawaharlal Nehru Centre For Advanced Cationic antibacterial composition
CA2954653C (en) * 2014-07-10 2023-01-24 The Scripps Research Institute N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
WO2018010475A1 (zh) * 2016-07-15 2018-01-18 上海来益生物药物研究开发中心有限责任公司 糖肽类衍生物及其药学可接受的盐、制备方法和应用

Also Published As

Publication number Publication date
JP7104424B2 (ja) 2022-07-21
AU2017348434A1 (en) 2019-05-16
EP3532483A4 (en) 2020-09-02
WO2018081797A1 (en) 2018-05-03
EP3532483A1 (en) 2019-09-04
AU2017348434B2 (en) 2021-10-07
US20200071359A1 (en) 2020-03-05
US10934326B2 (en) 2021-03-02
JP2019534289A (ja) 2019-11-28
CA3042039A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CA2828047C (en) Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
US11649222B2 (en) Compounds
CA3042039C (en) Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
Kloss et al. Mapping of the modular closthioamide architecture reveals crucial motifs of polythioamide antibiotics
WO2015179955A1 (en) Uba5 inhibitors
US10716797B2 (en) Steroid alkaloids and compositions and kits thereof
Pitcher et al. Development of 1, 2, 4-oxadiazole antimicrobial agents to treat enteric pathogens within the gastrointestinal tract
WO2018013890A1 (en) Methods for treatment of clostridium difficile infections
CA2954653C (en) N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
Wu et al. Exploration of the site-specific nature and generalizability of a trimethylammonium salt modification on vancomycin: A-ring derivatives
US9951039B2 (en) Pyrimidines for treatment of bacterial infections
Sampson et al. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI)
US9988341B2 (en) Bacterial topoisomerase inhibitors and use thereof
Payne Synthesis of FtsZ Inhibitors: Potential Antibiotic Agents
WO2013154793A1 (en) F2 derivatives as antibacterial agents
EP4139328A1 (en) Guanidine-modified c-terminus vancomycin compounds, compositions and methods
Bird Investigation of Thiopeptide Mechanism of Action for the Development of Thiopeptide Therapeutics

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220816

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250922

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108